Trastuzumab (Herceptin®) was first approved by the U.S. Food and Drug Administration (FDA) in 1998 for the treatment of human epidermal growth factor receptor (HER2) positive breast cancer (1). This evidence concerns the gene ERBB2 and breast carcinoma.